SCHEMBL11926302

SCHEMBL11926302

NC(=O)c1ccc(NC(=O)c2cc(OCCN3CCOCC3)nc(N3CCOCC3)n2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 3/20 0.47
▸ HIF1A Q16665 1/20 0.42
▸ EPAS1 Q99814 1/20 0.42
▸ OPRM1 P35372 2/20 0.42
▸ OPRD1 P41143 2/20 0.42
▸ OPRK1 P41145 2/20 0.42
▸ F10 P00742 1/20 0.41
▸ CHUK O15111 3/20 0.40
▸ INSR P06213 3/20 0.40
▸ MAPK8 P45983 3/20 0.40
▸ CAMKK2 Q96RR4 3/20 0.40
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GPR55 Q9Y2T6 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ PIK3R1 P27986 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL423803 0.84 KDR (0.46) MTORKDRPIK3CAEPHX2
SCHEMBL3232359 0.82 HTT (0.52) MTORLMNAPOLBHTTHSD17B10
SCHEMBL430042 0.80 FLT3 (0.46) LMNAKDRFLT3
SCHEMBL11926366 0.79 GRM4 (0.46) KDRFLT3EPHX2
SCHEMBL11926382 0.79 MAPT (0.48) MTOREPHX2
SCHEMBL3111569 0.79 EPHX2 (0.54) MTORPIK3CAEPHX2
SCHEMBL430618 0.79 GRM4 (0.49) POLB
SCHEMBL11926370 0.78 RAB9A (0.53) LMNAPOLB
SCHEMBL11926304 0.78 KDR (0.47) KDREPHX2
SCHEMBL11926374 0.78 KDM4E (0.51) LMNAKDRPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 — — US disclosed
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 — — US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG MTOR 578/4885HIF1A 809/4885EPAS1 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback